EGFR and lung cancer: These so‐called gene signatures (GSs) are usually derived by correlating patients’ survival data with gene expression data through Cox proportional hazards modeling.8 Many such GSs for lung cancer have been reported,9 but most have not been examined for their prognostic effectiveness with regard to the aforementioned ACT, TP53 and EGFR mutation status, and PD‐L1 expression, or have been examined for one or more but not all of these conditions.